Targets › EDNRB
7 programs from 6 companies in 14 trials: 6 Phase 3, 5 Phase 2, 3 Phase 4; Neurology, Cardiovascular, Other; next expected readout Nov 2026.
Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P24530)
Open in Phaseline: the race on EDNRB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pharmazz | Sovateltide ETB receptor agonist | EDNRB | Phase 4 | Acute Cerebral Ischemia; Acute Ischemic Stroke; Hypoxic-Ischemic Encephalopathy | Nov 2026 |
| Johnson & Johnson (Janssen) | Macitentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 3 | Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Combined Pre- and Post-capillary Pulmonary Hypertension | Jan 2027 |
| University Hospital, Grenoble | bosentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 3 | Ischemic Optic Neuropathy | Feb 2027 |
| University of Edinburgh | Bosentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 2 | Large Vessel Vasculitis | Jul 2027 |
| Noorik Biopharmaceuticals | Ambrisentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 2 | Hepatorenal Syndrome; IgA Nephropathy; Pulmonary Arterial Hypertension (PAH) | – |
| University Hospital, Rouen | Bosentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 2 | Resistant Hypertension | – |
| Pharmazz | PMZ-1620 Endothelin-B receptor agonist | EDNRB | Phase 2 | Acute Spinal Cord Injury | – |
Hypertension, Pulmonary (2) Ischemic Optic Neuropathy (1) Acute Spinal Cord Injury (1) Acute Cerebral Ischemia (1) Acute Ischemic Stroke (1) Hypoxic-Ischemic Encephalopathy (1) Hepatorenal Syndrome (1) IgA Nephropathy (1) Pulmonary Arterial Hypertension (PAH) (1) Resistant Hypertension (1) Large Vessel Vasculitis (1) Pulmonary Arterial Hypertension (1)
small molecule (5), protein or peptide (2)
Pharmazz (2) University Hospital, Grenoble (1) Noorik Biopharmaceuticals (1) University Hospital, Rouen (1) University of Edinburgh (1) Johnson & Johnson (Janssen) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.